Reata Pharmaceuticals Inc (RETA) - Financial Analysis Review - GlobalData - Company Reports

Reata Pharmaceuticals Inc (RETA) - Financial Analysis Review

Reata Pharmaceuticals Inc (RETA) - Financial Analysis Review - GlobalData - Company Reports
Reata Pharmaceuticals Inc (RETA) - Financial Analysis Review
Published Nov 29, 2016
33 pages — Published Nov 29, 2016
Price US$ 125.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Reata Pharmaceuticals Inc (RPI) focuses on the development of novel therapeutics to treat life-threatening diseases. It develops drugs for various therapeutic areas which includes cardiovascular; ophthalmology; immune-oncology and rare diseases. The companys lead product candidate, bardoxolone methyl is used for the treatment of pulmonary arterial hypertension and pulmonary hypertension. RPIs another pipeline product; omaveloxolone helps to treat multiple diseases. It works in partnership with academics as well as other biotechnology and pharmaceutical companies to develop technologies which target core pathophysiological processes entailed in driving intractable diseases.

GlobalData's Reata Pharmaceuticals Inc (RETA) - Financial Analysis Review provides a comprehensive insight into the company's history, business structure and operations. The report contains information on the company's key employees, key competitors and major products and services, as well as detailed financial ratios for the last 5 years.

Reata Pharmaceuticals Inc Key Recent Developments:

Nov 14,2016: Reata Pharmaceuticals Announces Third Quarter 2016
Oct 11,2016: Reata Pharmaceuticals Appoints Dawn Carter Bir as Vice President and Chief Commercial Officer
Aug 11,2016: Reata Pharmaceuticals Announces Second Quarter 2016 Financial and Operating Results


This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope
- Business description - A detailed description of the company's operations and business divisions.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives' employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as detailed business description and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services.
- Examine potential investment and acquisition targets with this report's detailed insight into the company's business, financial and operational performance. Financial ratios presented for major public companies in the report include; revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

  
Source:
Document ID
GDPH136970FA
Country
Industry
Ticker
RETA=US
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables31
  List of Figures41
Section 1 - About the Company41
Reata Pharmaceuticals Inc - Key Facts51
Reata Pharmaceuticals Inc - Key Employees61
Reata Pharmaceuticals Inc - Major Products and Services71
Reata Pharmaceuticals Inc - Pharmaceutical Pipeline Products Data83
  Reata Pharmaceuticals Inc, Pipeline Products by Therapy Area81
  Reata Pharmaceuticals Inc, Pipeline Products by Development Phase92
Reata Pharmaceuticals Inc - History111
Reata Pharmaceuticals Inc - Locations And Subsidiaries121
  Head Office121
  Other Locations &Subsidiaries121
Section 2 Company Analysis131
Company Overview131
Reata Pharmaceuticals Inc - Key Competitors141
Section 3 Company Financial Ratios151
Financial Ratios - Capital Market Ratios151
Financial Ratios - Annual Ratios162
Performance Chart181
Financial Performance181
Financial Ratios - Interim Ratios191
Financial Ratios - Ratio Charts201
Section 4 Company s Lifesciences Financial Deals and Alliances212
  Reata Pharmaceuticals Inc, Pharmaceuticals &Healthcare, Deals By Year, 2010 to YTD 2016211
  Reata Pharmaceuticals Inc, Pharmaceuticals &Healthcare, Deals By Type, 2010 to YTD 2016221
Reata Pharmaceuticals Inc, Recent Deals Summary231
Section 5 Company s Recent Developments241
Nov 14, 2016: Reata Pharmaceuticals Announces Third Quarter 2016242
Oct 11, 2016: Reata Pharmaceuticals Appoints Dawn Carter Bir as Vice President and Chief Commercial Officer261
Aug 11, 2016: Reata Pharmaceuticals Announces Second Quarter 2016 Financial and Operating Results272
Section 6 Appendix295
  Methodology291
  Ratio Definitions294
  About GlobalData331
  Contact Us331
  Disclaimer331

Table Of Contents

GlobalData - Company Reports—GlobalData is an industry analysis specialist, providing business information products and services. These high quality company reports are created via a large research and analysis capability, drawing from extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
GlobalData - Company Reports. "Reata Pharmaceuticals Inc (RETA) - Financial Analysis Review" Nov 29, 2016. Alacra Store. Mar 29, 2024. <http://www.alacrastore.com/storecontent/GlobalData-Company-Reports/Reata-Pharmaceuticals-Inc-RETA-Financial-Analysis-Review-2087-64543>
  
APA:
GlobalData - Company Reports. (2016). Reata Pharmaceuticals Inc (RETA) - Financial Analysis Review Nov 29, 2016. New York, NY: Alacra Store. Retrieved Mar 29, 2024 from <http://www.alacrastore.com/storecontent/GlobalData-Company-Reports/Reata-Pharmaceuticals-Inc-RETA-Financial-Analysis-Review-2087-64543>
  
US$ 125.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Company Profiles from one place.